Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., Japan.
J Toxicol Sci. 2013;38(4):571-9. doi: 10.2131/jts.38.571.
T-cell dependent antibody response (TDAR) incorporating both primary and secondary responses to keyhole limpet hemocyanin (KLH) in canine models have not yet been fully understood. To develop a practical dog TDAR model, we characterized primary and secondary antibody responses by intravenous or intramuscular immunization of KLH twice at intervals of 8 days during a 28-day course of study. Primary immunization with KLH by both routes induced a maximum IgM response on 6 to 8 days after the treatment, whereas the IgG response started 6 to 8 days after the treatment with relatively low levels. Remarkable increases in anti-KLH IgG levels (about 10-times compared with the primary response) were produced 5 to 7 days after the secondary KLH immunization by both routes. These results indicate that IgM-predominant and IgG-predominant responses were respectively induced by the primary and secondary immunization. Furthermore, the intravenous route showed higher baseline titers of primary and secondary anti-KLH IgM responses, suggesting that intravenous immunization of KLH might be a more suitable method for immunotoxicity evaluation. No remarkable inter-individual variability was noted in our canine models. Treatment with cyclophosphamide at 2 mg/kg/day for a consecutive 28 days significantly suppressed primary and secondary anti-KLH IgM and IgG responses induced by KLH injection on Days 15 and 23 of CPA treatment. These results demonstrate that these experimental designs could provide valuable information about the influence on both the primary and secondary humoral immune responses in dogs when exposed to potential immunomodulatory drugs.
犬模型中 T 细胞依赖的抗体反应(TDAR)包括对血蓝蛋白(KLH)的初次和再次应答,但尚未完全了解。为了开发实用的犬 TDAR 模型,我们通过静脉或肌肉内免疫 KLH 两次,间隔 8 天,在 28 天的研究过程中,对初次和再次抗体应答进行了特征描述。两种途径的 KLH 初次免疫在治疗后 6 至 8 天内诱导最大的 IgM 应答,而 IgG 应答在治疗后 6 至 8 天开始,水平相对较低。两种途径的 KLH 二次免疫后 5 至 7 天,抗 KLH IgG 水平显著升高(与初次应答相比约增加 10 倍)。这些结果表明,初次和再次免疫分别诱导了 IgM 优势和 IgG 优势应答。此外,静脉途径显示出更高的初次和再次抗 KLH IgM 应答的基线滴度,表明 KLH 的静脉免疫可能是免疫毒性评估更合适的方法。我们的犬模型中没有观察到明显的个体间变异性。连续 28 天每天 2 毫克/千克的环磷酰胺治疗显著抑制了 CPA 治疗第 15 天和第 23 天 KLH 注射诱导的初次和再次抗 KLH IgM 和 IgG 应答。这些结果表明,这些实验设计可以为潜在免疫调节剂药物暴露对犬初次和再次体液免疫应答的影响提供有价值的信息。